Failed early
Human immunoglobulin g: reduce relapses and new lesions in relapsing MS
relapsing MS · FcRn / IgG reduction, IVIG, plasma exchange
Controlled phase 2 trials were negative.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 128
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2002 · Placebo-controlled · MSFT-NCT00220779
Other linked trials: 2
These linked trials do not set the status.
- MOSTStopped, other reason
Phase 3 · 2017 · Not randomised
- PREDICT trialStopped, other reason
Phase 3 · 2013 · Compared with glatiramer acetate, interferon beta-1a, interferon beta-1b
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Failed early
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error